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Abdominal aortic aneurysms (AAAs) are charac-
terized by a dramatic localized remodeling of the
extracellular matrix (ECM), the presence of an
inflammatory infiltrate of macrophages and lympho-
cytes, and an associated increase in production 
of matrix metalloproteinase (MMP) enzymes.1-9
Under these conditions, destruction of elastin fibers
and smooth muscle cells (SMCs) occurs, causing loss
of medial elasticity and strength.10-13 The conse-
quent inability of the vessel to resist the pulsatile
dilatations of the arterial circulation is associated
with intense compensatory collagen deposition14
and arterial expansion as the vessel wall weakens,
with aneurysm formation being the end result.15
Despite intense biochemical study, the pathogen-
esis of AAA remains obscure. Aneurysmal disease is
frequently associated with atherosclerosis, yet no
clear evidence has been presented to connect the
pathogenesis of the two. Many authors have sug-
gested distinct etiologies for these conditions.16-19
Strong evidence of a genetic predisposition exists,20-23
and the mode of inheritance was recently considered
to be autosomal dominant.24 Support for the con-
cept of an inherited genetic abnormality was provid-
ed by Ward,25 who revealed generalized arterial
dilatation in the vasculature of patients with AAAs.
Similarly, Baxter et al26 demonstrated that the pro-
portions of elastin and collagen were altered in the
nonaneurysmal segments of the aorta of patients
with infrarenal AAAs.
The use of end-stage tissue in biochemical analy-
sis of aneurysms has prevented the separation of pri-
mary etiologic events from secondary degenerative
changes within the arterial tissue. Many past studies
have relied on whole artery homogenates for their
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source material.1,27-29 However, the presence of an
inflammatory infiltrate and an altered cytokinetic
profile within the aneurysmal aorta has prevented
meaningful conclusions from being drawn regarding
enzyme status or ECM metabolism in the stages of
aneurysm formation that precede dilatation.
Typically, the presence and progression of AAA
have been associated with elevated levels of MMP
production within the vessel wall. MMP-1, MMP-3,
and MMP-9 have been identified in AAAs29-31 and
are commonly thought to be important in the patho-
genesis of the disease. However, it has recently been
suggested that MMP-2 derived from mesenchymal
cells may play a prominent role in the initiation of
ECM changes that bring about aneurysmal dilata-
tion. Freestone et al32 reported that MMP-2 was the
dominant elastolytic enzyme in the wall of small early
aneurysms, with MMP-9 becoming most prominent
as the inflammatory infiltrate increased in density.
The etiologic role of MMP-2 was further supported
by two preliminary studies,33,34 which demonstrated
increased production of MMP-2 by aneurysm-
derived SMCs as compared with age-matched non-
aneurysmal controls. Additionally, Davis et al35
recently reported that MMP-9 was found in similar
quantities in both aneurysmal and occlusive aortic
tissue, whereas MMP-2 messenger RNA (mRNA)
and protein levels were significantly higher in AAAs
than in atheromatous aorta or controls.
The aim of this study was to investigate the
process of elevated MMP-2 production demonstrat-
ed by SMCs derived from AAAs. Gene expression of
MMP-2 was quantified, and MMP-2 production by
other mesenchymal cell lines was investigated.
MATERIALS AND METHODS
Sample collection. All studies were performed
with the approval of our local ethics committee, and
tissue specimens were obtained only with informed
consent of the patients involved. Aortic wall biopsy
specimens (2 cm2) from AAAs were collected at the
time of aortotomy during operative aneurysm repair.
Samples were obtained from the aortic wall 2 cm dis-
tal to the left renal vein to standardize the collection
point. Control aortic specimens from patients with
aortoiliac atherosclerosis were similarly collected
from age-matched individuals undergoing aorto-
bifemoral grafting for iliac occlusive disease. In these
cases, the aortic diameter was less than 2.5 cm. There
was no difference between the groups in terms of
ages (Mann-Whitney test, P = .11, U = 11), and the
patient demographics are tabulated in Table I.
Similarly, skin biopsy specimens were harvested
from patients with AAA or with iliac atherosclerosis
at the time of first incision for the culture of dermal
fibroblasts. Skin biopsy specimens were obtained
from abdominal skin harvested below the umbilicus.
Again no age difference between the groups was
demonstrated (Mann-Whitney test, P = .27, U = 99,
Table I).
Saphenous vein samples were harvested from the
proximal long saphenous vein from patients under-
going coronary artery bypass grafting. All tissue
samples were transferred to the laboratory and
processed within 15 minutes of harvest.
SMC culture. All chemicals, reagents, and cell
culture media were purchased from Sigma (Poole,
United Kingdom), unless otherwise stated.
Under sterile conditions, the medial layer of the
aortic biopsy specimen was dissected, and explants
were prepared by cutting the medial tissue into 1-
mm3 pieces. Hematoxylin and eosin staining of the
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Fig 1. Graph illustrating rates of proliferation of SMCs
derived from patients with abdominal aneurysms (AAA)
or controls with atherosclerosis (Control). Values are
medians with 95% CI.
Fig 2. Gelatin zymogram of conditioned serum-free
SMC media from 105 cells (approximately 1.8 mg/mL),
illustrating the elevated production of MMP-2 by
aneurysm-derived SMCs (AAA) compared with controls
with atherosclerosis (AT). Positive control HT 1080
fibrosarcoma cell line.
medial layer validated the dissection. The explants
were placed into flasks with SMC medium (Roswell
Park Memorial Institute 1640 containing 50,000
IU/L penicillin and streptomycin and 2 mmol/L L-
glutamine [Life Technologies, Grand Island, NY])
and 10% fetal bovine serum. Cultures were main-
tained in a humidified atmosphere of 95% air and 5%
carbon dioxide at 37°C. The medium was partially
replenished on alternate days, and the outgrowth of
cells was monitored. Cultures were passaged when
approximately 75% confluent by treatment with
trypsin and EDTA.
Saphenous vein SMCs were derived in the same
way from tissue obtained from coronary artery graft-
ing. Identification of all cultured SMCs was con-
firmed by characteristic appearance in tissue culture
and by immunofluorescent staining of smooth mus-
cle α-actin. The presence of contaminating leuko-
cytes or fibroblasts was checked by staining with
appropriate antibodies at passage 2.
Dermal fibroblast culture. Under sterile condi-
tions, the dermis and epidermis were separated from
the underlying fat. Explants were prepared by cutting
the tissue into 1-mm3 pieces and were placed into cul-
ture, where they were treated as described above.
SMC replication rates. The proliferation rate of
aortic SMCs derived from patients with aneurysms
or iliac atherosclerosis was quantified. Trypsinized
cells were seeded into 24 well plates (Nunclon,
Hereford, United Kingdom) at a density of 104 cells
per well (5.5 × 103 cells per square centimeter),
where they quiesced for 48 hours in SMC medium
containing 0.4% fetal bovine serum. Normal SMC
medium was then added, and two wells were count-
ed every day for 16 days by means of a standard
hemocytometer chamber and trypan blue dye 
exclusion.
Collection of conditioned medium. Condi-
tioned media were collected from all SMCs and
fibroblast cell lines at passage 3 to assess the produc-
tion of MMPs and tissue inhibitor metalloproteinase
(TIMP). Trypsinized cells were seeded into six well
plates at a density of 105 cells per well (1.1 × 104 cells
per square centimeter), where they quiesced as
described above. A 1.5-mL serum-free medium
(QBSF 56, Sigma, Pool, United Kingdom) was
added to each well and collected after 48 hours. Cells
were counted after serum-free culture was collected.
Interleukin-1β (IL-1β) at 10 ng/mL (R & D
Systems, Abingdon, United Kingdom) was added to
selected cultures. Lysates were prepared from select-
ed cultures by freeze thawing the cells five times.
Conditioned media samples were analyzed with
gelatin zymography, Western blotting, and enzyme-
linked immunosorbent assay (ELISA). The protein
concentration of these samples was determined with
the use of Protein Assay Reagent (Bio-Rad, Hemel
Hempstead, Hertfordshire, United Kingdom).
Gelatin zymography. Ten percent gelatin zymo-
grams were prepared according to methods previous-
ly described,36 with the use of the Mini Protean II
electrophoresis system (Bio-Rad). Zymography is
useful because it permits the visualization of latent as
well as active MMP enzymes. Latent enzymes are
detected because they are activated during the final
incubation step, that is, after electrophoresis has
taken place. Therefore, they migrate according to
their appropriate molecular weight, become activat-
ed, and appear in the final stained gel. Bands of lysis
were assessed comparatively by means of scanning
densitometry with the use of an Imagemaster DTS
scanner and Imagemaster 1D software (Pharmacia
Biotech, Milton Keynes, United Kingdom). The
software measures both optical density and size of
each band and integrates the two to produce a single
value per band. Densitometry was carried out within
the limits of the linear range of the detection profile
of the equipment.
Western blotting. The MMPs and TIMP were
detected with a murine monoclonal primary antibody
(1 in 1000; Chemicon, Harrow, United Kingdom)
and a horseradish peroxidase–conjugated antimouse
immunoglobulin G secondary antibody (1 in 2000,
Amersham, Little Chalfont, United Kingdom).
Visualization of bands of immunologic reactivity was
performed with the ECL detection system
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Table I. Ages and aortic diameter from patients providing aortic SMCs and dermal fibroblasts*
AAA Atherosclerotic
Sample Age (y) Aortic diameter (cm) Age (y) Aortic diameter (cm)
SMCs 74.5 (67-81) 6.8 (5.5-9.0) 68.5 (58-75) < 2.5
Dermal fibroblast 69.0 (61-81) 7.0 (5.5-9) 64.0 (58-75) < 2.5
*Values are medians with ranges in parentheses.
(Amersham) according to the manufacturer’s proto-
col. Densitometric analysis was carried out as previ-
ously described.
ELISA. ELISA kits (Amersham) were used as
directed. Quantification of MMP-1, MMP-2,
MMP-3, MMP-9, TIMP-1, and TIMP-2 on all
SMCs and fibroblast-conditioned media was per-
formed, and the data were expressed as protein pro-
duction per 105 cells.
Isolation of total RNA from human cells.
Total RNA was isolated from cultured human cells
with Trizol reagent (Life Technologies) according to
the manufacturer’s protocol. The concentration of
the isolated RNA was determined spectrophotomet-
rically at 280 nm with a Gene-Quant analyzer
(Pharmacia Biotech).
Northern blotting. Northern analysis was used
to compare the level of expression of MMP and
TIMP genes among the SMCs derived from patients
with aneurysms and controls. One percent of agarose
and formaldehyde gels was prepared according to
methods previously described.37 Fractionated total
RNA was transferred to Hybond N nylon membrane
(Amersham) with the use of a standard vertical capil-
lary transfer apparatus. Membranes were placed into
hybridization tubes with 10-mL QuickHyb prehy-
bridization solution (Stratagene, La Jolla, Calif) con-
taining 1 mg of salmon sperm DNA and then placed
into a rotary oven at 65°C for 15 minutes.
Probes were prepared with the use of a reverse
transcriptase-polymerase chain reaction method
(Table II). Specific primers were used to amplify a
fragment of complementary DNA generated by
reverse transcription of HT1080 total RNA, with the
use of avian myeloblastosis virus reverse transcriptase
(Promega, Madison, Wis). This product was then
used as the template in a second polymerase chain
reaction that contained only the reverse primer to
generate a product complementary to the mRNA
transcript. Furthermore, radiolabeled deoxycytidine
triphosphate (3000 Ci/mmol/L; NEN, Boston,
Mass) was included in the latter reaction to produce
a high specific activity probe. Reactions were assem-
bled as directed in the Taq enzyme literature
(Promega) and were subject to the following cycling
conditions: 95°C for 5 minutes, 59°C for 1 minute,
72°C for 1 minute (1 cycle); 95°C for 1 minute,
59°C for 1 minute, 72°C for 1 minute (30 cycles);
and 95°C for 1 minute, 59°C for 1 minute, 72°C for
10 minutes (1 cycle). The labeled probe was added
directly to the appropriate hybridization tubes and
allowed to anneal for 2 hours at 65°C. Annealed
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Table II. Primers used in reverse transcriptase-polymerase chain reaction–based production of Northern
blot probes
MMP-2 forward ATT GAT GCG GTA TAC GAG GC 350 bp product
MMP-2 reverse GGC ACC CTT GAA GAA GTA GC
MT1-MMP forward TGC CCA ATG GAA AGA CCT AC 315 bp product
MT1-MMP reverse TGA TGA TCA CCT CCG TCT CC
TIMP-2 forward AAC GAC ATT TAT GGC AAC CC 250 bp product
TIMP-2 reverse ACC TGT GGT TCA GGC TCT TC
GAPDH forward AGA ACA TCA TCC CTG CCT C 350 bp product
GAPDH reverse GCC AAA TTC GTT TGC ATA CC
bp, Base pair.
Table III. Summary of ELISA test data from aneurysm-derived (AAA) and control SMCs (AT)–condi-
tioned serum-free media samples* 
Median concentration (ng/mL)†
AT AAA P value‡
MMP-1 12.88 (1.86-34.48) 12.13 (5.05-29.66) .8518
MMP-2 262.3 (124.9-452.3) 758.2 (422.4-1270.0) .0080
MMP-3 13.57 (5.89-24.83) 13.40 (5.73-31.25) .9497
MMP-9 32.17 (1.02-86.23) 27.36 (10.51-76.39) .7546
TIMP-1 570.8 (405.7-892.1) 678.0 (497.9-999.9) .6620
TIMP-2 17.37 (13.49-24.75) 19.93 (10.98-27.59) 1.0000
MMP-2–TIMP-2 ratio 14.35 (6.66-23.63) 38.34 (14.52-108.60) .0080
*Media was conditioned by 105 cells for 48 hours.
†Data are expressed as median concentration with 95% CI. 
‡P value determined by Mann-Whitney analysis.
probe was detected with autoradiography. Sample
normalization was assessed by comparing the intensi-
ty of bands generated by a glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe.
Statistical analysis. Unpaired data, such as
ELISA results, were analyzed with the use of Mann-
Whitney tests. Paired data, such as gel and blot scan-
ning data, were analyzed with the Wilcoxon test.
Cell proliferation data were analyzed by calculating
the area under the curve generated by each cell line,
then comparing the data sets with a Mann-Whitney
test. The four experimental groups of the serum
treatment experiments were compared with the use
of a Kruskal-Wallis nonparametric analysis of vari-
ance. Significance was assumed at the 5% level.
RESULTS
SMC proliferation rates. Proliferation rates of
SMCs derived from patients with AAA and controls
with atherosclerosis were assessed. Proliferation has
been associated with MMP expression,38,39 and any
data on gene expression would need to be correct-
ed, if proliferation rates were different in cell culture.
With analysis of area under the curve, the prolifera-
tion rates for the two cell types were not found to be
significantly different (Mann-Whitney test, n = 12,
U = 15.00, P = .6991, Fig 1).
MMP and TIMP production from SMCs.
Gelatin zymography analysis of SMC-conditioned
media, normalized by cell number, revealed gela-
tinolytic activity of approximately 70 kd in all samples.
This activity was abolished by incubation of the gel
with the metal ion chelating agent 1,10-phenanthro-
line. Western blot analysis indicated immunoreactivity
consistent with this band of proteolysis when an
anti–MMP-2 monoclonal antibody is used. The level
of production of this activity was unchanged after the
addition of IL-1β, and no further activity was detect-
ed in cell lysates, which suggested that this protease
was not stored intracellularly (data not shown).
Scanning densitometric analysis of zymograms
revealed that aneurysm-derived SMCs produced sig-
nificantly more MMP-2 into the culture medium
than control cells (Wilcoxon analysis, n = 14, W =
34.00, P = .0234, Fig 2). All of the MMP-2 was in
the latent state.
Analysis of Western blots with the use of an
anti–TIMP-2 antibody suggested that the level of
TIMP-2 expression was not significantly different
between control and aneurysm cells (n = 14, W =
9.00, P = .4375). ELISA analysis confirmed the
results obtained with zymography and Western blot-
ting (Table III). These data suggested that there was
no MMP activity other than MMP-2 in the condi-
tioned media samples, that MMP-2 production, and
the MMP-2–TIMP-2 ratio was significantly elevated
in aneurysm-derived SMCs compared with controls.
Northern blotting with an MMP-2–specific
probe revealed reactivity in both aneurysm and con-
trol lanes around 3 kilobase (kb), consistent with the
MMP-2 transcript (Fig 3). Scanning densitometry
demonstrated a significantly elevated level of expres-
sion in aneurysm SMCs compared with control cells
(Wilcoxon test, n = 14, W = –21.00, P = .0313, Fig
4). Calculation of the MMP-2–GAPDH ratio also
indicated a significant elevation of MMP-2 expres-
sion by aneurysmal SMCs (n = 14, W = 8.00, P =
.0426). Northern analysis of TIMP-2 and mem-
brane type 1 (MT1)–MMP revealed transcripts
around 4 kb and 1.6 kb, respectively, but densitom-
etry suggested that the levels of both were not sig-
nificantly different between the samples (MT1-
MMP: n = 14, W = –3.00, P = .8438; TIMP-2: n =
14, W = –3.00, P = .8438, Figs 3 and 4).
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Table IV. Summary of ELISA test data from aneurysm-derived (AAA) and control dermal fibroblast
(AT)–conditioned serum-free media samples*
Median concentration (ng/mL)†
AT AAA P value‡
MMP-1 63.06 (0-138.3) 19.38 (7.68-70.96) .364
MMP-2 779.6 (601.0-1097.0) 662.5 (473.8-1056.0) .284
MMP-3 35.02 (17.55-62.74) 21.28 (12.85-31.23) .045
MMP-9 113.1 (66.37-152.2) 107.0 (64.38-132.4) .724
TIMP-1 599.1 (395.2-795.6) 426.2 (337.4-540.2) .147
TIMP-2 19.44 (10.88-24.72) 14.46 (12.01-21.07) .797
MMP-2–TIMP-2 ratio 60.52 (27.12-77.50) 45.73 (30.12-67.02) .7242
*Media was conditioned by 105 cells for 48 hours.
†Data are expressed as median concentration with 95% CI.
‡P value determined by Mann-Whitney analysis.
MMP and TIMP production from fibro-
blasts. Analysis of MMP-2 production from SMCs
demonstrated a significant elevation of MMP-2
expression from cells derived from aortic aneurysms.
Interestingly, zymography and ELISA analyses of
conditioned media from aneurysm-derived and
atheromatous control dermal fibroblasts revealed no
significant differences in MMP-2 production. As
with the SMCs, only MMP-2 and TIMP-1 and
TIMP-2 were detected in the media samples of 
the dermal fibroblasts. Scanning densitometry of
zymography gels revealed that MMP-2 levels were
not significantly different (n = 32, W = 38.00, P =
0.333, Fig 5). ELISA data confirmed that there was
no significant difference in MMP or TIMP produc-
tion among the fibroblast cell lines (Table IV).
Scanning densitometry of Northern blots confirmed
the similar level of MMP-2 gene expression (n = 32,
W = 14.00, P = .3828) between the aneurysm- and
atherosclerotic-derived cells.
DISCUSSION
In the current study, data have been presented to
suggest that SMCs derived from aneurysmal aorta
produced elevated levels of MMP-2. Northern blot-
ting demonstrated that this was due to significantly
increased transcription of the MMP-2 gene in SMCs
derived from aortic aneurysms as compared with
controls with atherosclerosis. Although MMPs
appear to be secreted soon after translation,40 we
examined the possibility that temporary intracellular
storage of the enzyme may explain the varied level of
production. SMC lysates revealed no further MMP-
2 activity on gelatin zymograms, which suggested
that no significant amount of enzyme was stored and
that protein synthesis occurred de novo in relation
to gene transcription.
Analysis of TIMP-2, the physiologic inhibitor of
MMP-2, with Western blotting, ELISA, and RNA
analysis revealed no difference in the level of expres-
sion between SMCs derived from patients with AAA
or those with aortoiliac atheroma. The elevated pro-
duction of MMP-2 from the aneurysm-derived aor-
tic SMCs, combined with unchanged TIMP-2 pro-
duction, may modulate an environment of increased
net elastolysis in aortas prone to aneurysm forma-
tion. The MMP-2–TIMP-2 ratio was more than 2.5
times elevated in the aneurysm-derived cells.
Interestingly, the MMP-2 secreted by SMCs in
this study was exclusively in the latent form, which
alone will not bring about elastolysis. For degradation
of elastin or other ECM components, pro–MMP-2
must first be activated. This is achieved by cleaving 
the propeptide to expose the active site of the
enzyme.41,42 In vivo, the MT-MMPs, in complex
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Fig 3. Northern blot of SMC RNA, 5 µg per lane, detect-
ed with MMP-2, MT1-MMP, and TIMP-2 probes, illus-
trating the increased level of transcript in the aneurysm-
derived SMCs (AAA) compared with controls (AT ).
GAPDH signal was used to normalize loading.
Fig 4. Graph illustrating scanning densitometry data for
Northern blot analysis of SMC RNA detected with MMP-
2, MT1-MMP, and TIMP-2 probes. Individual data
points are illustrated with median values. Cells derived
from patients with abdominal aneurysms (AAA) com-
pared with controls with atherosclerosis (AT ). Positive
control HT 1080 fibrosarcoma cell line.
with TIMP-2,43 are the physiologic activators of
MMP-2.44 Data from the current study have demon-
strated the expression of MT1-MMP from aortic vas-
cular SMCs, and so these cells appear capable of pro-
ducing all the biochemical requirements for MMP-2
activation.
The knowledge that most abdominal aortic
SMCs are embryologically derived from meso-
derm45 led to the hypothesis that the elevated level
of MMP-2 production from patients with AAA may
be detected in other mesenchymal cells. Thus, the
MMP-2/TIMP-2/MT1-MMP profile was deter-
mined in dermal fibroblasts harvested from patients
with AAA or aortic atherosclerosis. These two
groups of dermal fibroblast cell lines produced
equivalent levels of MMP-2 and TIMP-2. These
data suggested that the elevated MMP-2 expression
in SMCs from aneurysmal aorta was not a general-
ized finding in all mesenchyme-derived tissues and
may be tissue specific in nature. Further studies in
which an alternative source of vascular SMCs is used
will be required to establish this precept.
The reasons for the elevated SMC MMP-2 gene
transcription in aortic SMCs derived from patients
with AAA are unclear. No mutational abnormalities
in the MMP-2 gene itself have been reported, and
the differences may be due to altered regulation.
The MMP-2 gene is constitutively expressed, and
lacks the TPA-responsive elements present in
inducible MMP gene promoters. It also lacks a
TATA box, an observation common to other house-
keeping gene promoters.46 It is unclear how its level
of expression may readily be modulated. MMP-2 has
previously been demonstrated to be unresponsive to
cytokinetic influences,47 and the lack of response to
IL-1β in this study confirmed these findings.
However, Davis et al35 recently revealed that mes-
enchymal MMP-2 production was most prominent
in areas of inflammation in AAAs and suggested
paracrine modulation of the MMP-2 gene.
Control of gene expression may be imparted at
many levels. However, few examples of this are appar-
ent for the MMP-2 gene. Increased transcription may
be the result of a tissue-specific upstream enhancer
element, as seen in glomerular mesangial cells,48
which constitutively express high levels of MMP-2.
Alternative explanations include altered mRNA stabil-
ity or a semipermanent modulation of the SMC phe-
notype after long-term exposure to high levels of
inflammatory cytokines. However, the latter is unlike-
ly to be maintained after two or three passages in cul-
ture. Furthermore, the difference may be explained
by the derivation of some SMCs from atherosclerotic
plaque, thus representing a different phenotype.
However, all our tissue samples were derived from tis-
sue containing atherosclerotic lesions, and we are sat-
isfied that our dissection technique eliminated this
potential for uncertainty. In conclusion, the current
data suggested that SMCs derived from AAAs were
genetically predisposed to elevated MMP-2 expres-
sion. Further experiments to investigate mRNA sta-
bility, polymorphism screening of promoter variation,
and electrophoretic mobility shift assays will be
required to investigate these findings further.
The studies of Freestone et al32 and Davis et al35
have implicated MMP-2 in aneurysm pathogenesis.
The findings from this study have presented further
evidence that a predisposition to elevated MMP-2
expression in the SMCs of patients with AAAs may
significantly contribute to the events preceding aortic
dilatation. It is possible to envisage a hypothesis of
MMP-2–driven aneurysm expansion, where mes-
enchyme-mediated elastolysis may liberate elastin-
derived peptides from the arterial media. These
breakdown products of elastin degradation may then
attract an inflammatory infiltrate causing further
ECM degradation and loss of vessel wall integrity.
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